Franklin Resources Inc. Purchases 248,038 Shares of Hims & Hers Health, Inc. $HIMS

Franklin Resources Inc. raised its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 53.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 712,861 shares of the company’s stock after purchasing an additional 248,038 shares during the quarter. Franklin Resources Inc. owned 0.32% of Hims & Hers Health worth $35,536,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HIMS. Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 1.5% during the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after acquiring an additional 71,593 shares during the period. Northern Trust Corp raised its stake in shares of Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. BIT Capital GmbH raised its stake in Hims & Hers Health by 7.4% in the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after buying an additional 112,949 shares during the last quarter. Finally, State of Michigan Retirement System raised its position in shares of Hims & Hers Health by 84.9% in the 2nd quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock valued at $68,748,000 after purchasing an additional 633,300 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Finally, Bank of America boosted their target price on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $45.27.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 13,749 shares of the business’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the completion of the transaction, the insider directly owned 297,139 shares of the company’s stock, valued at $15,005,519.50. The trade was a 4.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $53.48, for a total transaction of $6,852,231.96. Following the sale, the chief executive officer owned 160,425 shares in the company, valued at $8,579,529. The trade was a 44.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 616,431 shares of company stock worth $32,924,482. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Trading Up 3.9%

Shares of HIMS stock opened at $38.54 on Thursday. Hims & Hers Health, Inc. has a 1-year low of $23.97 and a 1-year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company has a 50-day moving average of $48.27 and a two-hundred day moving average of $50.85. The firm has a market cap of $8.77 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 7.38 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the previous year, the firm earned $0.32 EPS. The firm’s revenue for the quarter was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.